Browsing by Author "Khanna, N."

Now showing 1 - 7 of 7

Comparison of recombinant protein and cell lysate antigens for detection of anti-chikungunya (CHIK) IgM antibody
(University of Kelaniya, 2011) Athapaththu, A.M.M.; Abeyewickreme, W.; Hapugoda, M.; Khanna, N.; Inouve, S.; Tun, M.M.N.; Gunasena, S.
Chikungunya (CHIK) virus specific antigen which has high specificity and low cross reactivity with other related diseases is required for laboratory confirmation. The objective of this study is to compare two antigens for detection of anti-CHIK antibody. In this study, two antigens (viral cell lysate and recombinant protein) were evaluated for detection of anti-CHIK antibody by using IgM ELISA. A novel recombinant protein antigen was designed based on envelope domain, a critical antigenic region of the major structural protein. This protein was expressed in Escherichia coli and resultant protein was affinity purified and 10mg with >95% of purity per liter of culture was obtained. Cell lysate antigen was prepared using a crude culture fluid. Two antigens were evaluated separately using a panel of well characterized serum samples obtained from the Dept. of Virology (WHO Reference Centre for Viral Reference and Research), Institute of Tropical Medicine, Nagasaki University. A total of 64 serum samples confirmed as positives and 22 confirmed as negatives were used to evaluate the antigens. Specificity and sensitivity of the recombinant protein antigen was 48% and 90% respectively. Specificity and sensitivity of the viral lysate antigen was 17% and 100% respectively. Viral lysate antigens can cause biohazard risk, high production cost and cross reactivity with other organisms of the same genus/family. Recombinant protein antigen which shows high specificity and sensitivity used in this study is important to overcome problems associated with viral lysate antigen. Testing of a large number of samples is needed to reconfirm this finding. Acknowledgment: Financial assistance and technical co-operation by International Center for Genetic Engineering and Biotechnology (ICGEB CRP SRL 08/02), National Science Foundation (NSF/RG/2009/BT/01) and International Atomic Energy Authority (IAEA/SRL/5/042) is acknowledged.
Comparison of recombinant protein and cell lysate antigens for detection of anti-chikungunya (CHIK) IgM antibody
(Sri Lanka College of Microbiologists, 2011) Athapaththu, A.M.M.H.; Khanna, N.; Inouve, S.; Gunasena, S.; Abeyewickreme, W.; Hapugoda, M.D.
INTRODUCTION: Chikungunya (CHIK) virus specific antigen which has high specificity and low cross reactivity with other related diseases is required for laboratory confirmation. OBJECTIVE: To compare two antigens for detection of anti-CHIK antibody. DESIGN, SETTING AND METHODS: In this study, two antigens {viral cell lysate and recombinant protein) were evaluated for detection of anti-1 CH IK antibody by using IgM ELISA. A novel recombinant | protein antigen was designed based on envelope domain, a critical antigenic region of the major structural protein, I This protein was expressed in Escherichia coli and resultant protein was affinity purified and ~10mg with >95% of purity per liter of culture was obtained. Cell lysate antigen was prepared using a crude culture fluid. Two antigens were evaluated separately using a panel of well characterized serum samples obtained from the Dept. of Virology (WHO Reference Centre for Viral Reference and Research), Institute of Tropical Medicine,] Nagasaki University. RESULTS: Atotal of 64 serum samples confirmed as positives andl 22 confirmed as negatives were used to evaluate the antigens. Specificity and sensitivity of the recombinant protein antigen was 48% and 90% respectively. Specificity and sensitivity of the viral lysate antigen was] 17% and 100% respectively. Conclusion Viral lysate antigens can cause biohazard risk, high production cost and cross reactivity with other organisms of the same genus/family. Recombinant protein antigen which shows high specificity and sensitivity used in this study is important to overcome problems associated with viral lysate antigen. Testing of a large number of samples is needed to reconfirm this finding. ACKNOWLEDGMENT: Financial assistance and technical co-operation by International Center for Genetic Engineering and Biotechnology (ICGEB CRP SRL 08/02), National Science Foundation (NSF/RG/2009/BT/01) and International Atomic Energy Authority (IAEA/SRL/5/042) is acknowledged.
Development of recombinant protein antigens using a bacterial expression system for the detection of anti-Chikungunya (CHIK) antibodies
(Sri Lanka College of Microbiologists, 2013) Athapaththu, A.M.M.H.; Khanna, N.; Inouve, S.; Gunasena, S.; Abeyewickreme, W.; Hapugoda, M.
INTRODUCTION AND OBJECTIVE: Laboratory confirmation of Chikungunya (CHIK) virus is very useful as clinical symptoms of CHIK can overlap with other diseases. Chikungunya virus specific antigen, which shows high specificity, sensitivity and low cross reactivity with other related diseases, is required for laboratory confirmation. Objective of this study was to develop and compare two recombinant protein antigens for detection of anti-CHIK antibodies. DESIGN, SETTING AND METHODS: Recombinant CHIK protein antigens were prepared using Envelope (E1 and E2) regions of the CHIK virus. The genes were custom designed and chemically synthesized with a 6X His tag. Bacterial expression systems [BL21 (DE3)] were used to clone and express the recombinant proteins. The recombinant proteins were purified with >95% of purity per liter of culture using Ni-NTA columns under denature conditions. In this study, two antigens were evaluated for detection of anti-CHIK antibody by using novel optimized in-house IgM and IgG ELISAs, using a panel of well characterized serum samples obtained from the Dept. of Virology (WHO Reference Center for Viral Reference and Research) Institute of Tropical Medicine, Nagasaki University, Japan. RESULTS: Atotal of 55 serum samples confirmed as positives and 186 confirmed as negatives by HA! test, IgM capture ELISA and indirect IgG ELISA using the purified CHIK antigen were used to evaluate the antigens using novel IgM ELISA. A total of 78 serum samples confirmed as positives and 148 (E1) or 227 (E2) (148 + extra 79) confirmed ac negatives were used to evaluate the antigens using novel IgG ELISA. The E1 recombinant protein showed 5% (3/ 55) sensitivity and 99% (184/186) specificity for IgM ELISA and 60% (47/78) sensitivity and 63% (94/148) specificity for IgG ELISA. The E2 recombinant protein showed 65% (36/55) sensitivity and 70% (131/186) specificity for IgM ELISA and 83% (65/78) sensitivity and 86% (195/227) specificity for IgG ELISA. CONCLUSION: Recombinant CHIK-E2 protein antigen showed higher specificity and sensitivity in detection of both IgM and IgG antibodies. Thus the E2 recombinant protein antigen used in this study could be expressed in an eukaryotic expression system to achieve much higher results. ACKNOWLEDGMENT: International Center for Genetic Engineering and Biotechnology (ICGEB CRP SRL 08/02), National Science Foundation (NSF/RG/2009/BT/01) and International Atomic Energy Authority (lAEA/SRL/5/042) are gratefully acknowledged.
Development of recombinant proteins as diagnostic intermediates for chikungunya infection
(Sri Lanka Association for the Advancement of Science, 2010) Athapaththu, A.M.M.H.; Khanna, N.; Gunasena, S.; Abeyewickreme, W.; Hapugoda, M.D.
Chikungunya is an important disease with explosive outbreaks occurring in many South East Asian countries. As the clinical symptoms associated with chikungunya viral infections are often indistinguishable from those of many other viral, bacterial and parasitic infections confirmation of chikungunya outbreaks is important for clinicians for proper management of patients and for vector control programmers. Laboratory diagnosis of chikungunya in Sri Lanka is hindered by the non-availability of reliable commercial diagnostic kits and inaccessibility to reagents. There is a need to develop an assay that can confirm chikungunya, produced at low cost and easily standardized for the use in field settings. Currently available laboratory diagnostic kits depend on ELISA based on whole viral antigens which cause biohazard risk, high production cost and cross reactivity with other organisms of the same genus/family. Therefore, a diagnostic intermediate using a single recombinant protein antigen to overcome problems associated with whole viral antigen/lysate is important. The objective of this study was to assist laboratory confirmation of outbreaks through developing competencies for a rapid laboratory diagnostic method using recombinant protein antigens for chikungunya infection. We have designed 2 novel recombinant protein antigens based on Envelope domain (E), a critical antigenic region of the major structural protein of chikungunya virus. They were expressed in Escherichia coli separately, and resultant proteins were affinity purified and obtained ~5mg and 10mg respectively and protein of >95% purity per liter of culture. These 2 proteins were evaluated as potential diagnostic intermediates in ELISA separately for the detection of anti-chikungunya Immunoglobulin M (IgM) antibody using a panel of well characterized serum samples. E1 and E2 showed 60% and 67% positivity respectively. Specificity proteins were tested using serum from healthy volunteers and infected with other viral diseases. Two proteins could detect only anti-chikungunya IgM antibodies. We demonstrated that these 2 novel recombinant protein antigens can function as diagnostic intermediates. Acknowledgements: Financial assistance from the International Centre for Genetic Engineering and Biotechnology (ICGEB CRP/ SRI08 02) and International Atomic Energy Agency (IAEA SRI TC 5-042) are gratefully acknowledged
Enzyme-linked Immunosorbent Assay (ELISA) using recombinant protein antigens for detection of anti-chikungunya antibodies
(Faculty of Tropical Medicine, Mahidol University, 2010) Athapaththu, A.M.M.H.; Khanna, N.; Abeyewickreme, W.; Gunasena, S.; Hapugoda, M.D.
OBJECTIVES: Chikungunya is a mosquito borne viral infection that has caused great medical and public health problems in South East Asia during last few years. Currently available laboratory diagnostic kits depend on Enzyme-Linked Immunosorbent Assay (ELISA) based on whole viral antigens caused biohazard risk, high production cost and cross reactivity with other organisms of the same genus/family. These problems can be avoided by using recombinant protein antigens in ELISAs. METHODOLOGY: Two novel recombinant protein antigens based on Envelope (E) domain, a critical antigenic region of the major structural protein of chikungunya virus were expressed separately in a bacterial expression system (Escherichia coli). Two proteins were purified under denatured conditions. They were evaluated as potential diagnostic intermediates for detection of and-chikungunya antibodies in Immunoglobulin M (IgM) and Immunoglobulin G (IgG) ELISAs separately using a panel of serum samples confirmed by the gold standard assay, Heamagglutination Inhibition (HAI) assayRESULTS: These 2 protein antigens: El and E2 showed more than 60% positivity in IgG ELISAs and IgM ELISAs. A field validation using a large number of serum samples should be done for further confirmation of these results. It can be concluded that these 2 novel recombinant protein antigens can be used as a diagnostic intermediate to detect anti-chikungunya antibodies. ACKNOWLEDGEMENTS: Financial assistance from the International Centre for Genetic Engineering and Biotechnology (1CGEB CRP/ SRI08-02) is gratefully acknowledged
Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes
(American Society for Microbiology, 2007) Hapugoda, M.D.; Batra, G.; Abeyewickreme, W.; Swaminathan, S.; Khanna, N.
The resurgence of dengue (DEN) virus infections in the last few decades coupled with the lack of a preventive vaccine and specific antiviral drugs has jointly contributed to making this a significant global public health problem. Currently, symptomatic supportive treatment and fluid replacement therapy are the only means available to minimize DEN-induced mortality. As the clinical symptoms associated with DEN virus infections are indistinguishable from those of many other viral, bacterial, and parasitic infections, specific diagnostic tests assume critical importance in the unequivocal identification of DEN virus infections. We have designed a novel chimeric antigen based on envelope domain III (EDIII), a critical antigenic region of the major structural protein of DEN viruses. We fused EDIIIs corresponding to each of the four DEN virus serotypes using pentaglycyl linkers, over expressed the resultant tetravalent chimeric protein in Escherichia coli, and affinity purified it in high yields, obtaining approximately 30 mg protein of >95% purity per liter of culture. We show that this tetravalent antigen could specifically recognize anti-DEN virus antibodies of both the immunoglobulin M (IgM) and IgG classes. Using a large panel of IgM antibody capture-enzyme-linked immunosorbent assay- and hemagglutination inhibition-confirmed DEN virus-infected and uninfected patient sera (n = 289), we demonstrate that this tetravalent antigen can function as a diagnostic tool of high sensitivity and specificity.
Tetravalent dengue specific domain III based chimeric recombinant protein as dengue diagnostic intermediates for the detection of both anti-dengue immunoglobulin M(IGM) and imunoglobulin G(IGG) antibodies in human serum samples.
(International Water Management Institute, 2006) Hapugoda, M.D.; Abeyewickreme, W.; Gunasena, S.; Khanna, N.
BACKGROUND: Dengue infection is an important mosquito borne viral infection caused by four serotypes of dengue virus with explosive outbreaks occurring in many tropical areas. Laboratory diagnosis of the disease mainly depends on Enzyme-Linked Immunosorbent Assay (ELISA) based on whole viral antigens which cause biohazard risk, high production cost and cross reactivity with other flaviviruses. OBJECTIVES: To produce a recombinant protein antigen to overcome problems associated with whole dengue viral antigen/lysate or recombinant whole envelope protein. STUDY DESIGN: We have designed and expressed a single recombinant tetravalent protein antigen which contains Domain III of envelope protein from all four serotypes of dengue virus, linked with each other through penta glycine linkers. This synthetic gene was expressed in Escherichia coli and protein was purified using a single affinity chromatographic step. We developed Immunoglobulin M (IgM) and Immunoglobulin G (IgG) ELISAs using this novel protein as the capture antigen. The antigen was validated as a diagnostic reagent on serum samples. RESULTS: 30 mg of recombinant protein per litre of culture could be purified. Both ELISAs developed using this novel recombinant protein showed an excellent agreement with a commercially available IgM ELISA (MRL diagnostic) and haernagglutination inhibition assay respectively. Conclusions: Findings of this study suggests that this single dengue specific tetravalent recombinant protein antigen can be used as a diagnostic intermediate for detection of dengue infection.